Crystallinity: A Complex Critical Quality Attribute of Amorphous Solid Dispersions-Reference-Cited by-同舟云学术

Crystallinity: A Complex Critical Quality Attribute of Amorphous Solid Dispersions

Published:2023-09-12 Issue:10 Volume:20 Page:4802-4825
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Moseson Dana E.¹²^ORCID,Taylor Lynne S.¹^ORCID

Affiliation:

1. Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States

2. Worldwide Research and Development Pfizer, Inc., Groton, Connecticut 06340, United States

Funder

Division of Graduate Education

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.3c00526

Reference201 articles.

1. Enabling an HCV Treatment Revolution and the Frontiers of Solid Solution Formulation

2. Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview

3. Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies

4. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs

5. ICH Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. ICH Harmonised Tripartite Guideline; European Medicines Agency, 1999.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of rheology in formulation and process design of hot melt extruded amorphous solid dispersions;International Journal of Pharmaceutics;2024-10

2. Amorphous Solubility Advantage: Theoretical Considerations, Experimental Methods, and Contemporary Relevance;Journal of Pharmaceutical Sciences;2024-09

3. Surfactant–Polymer Complexation and Competition on Drug Nanocrystal Surfaces Control Crystallinity;ACS Applied Materials & Interfaces;2024-06-18

4. Trends in amorphous solid dispersion drug products approved by the U.S. Food and Drug Administration between 2012 and 2023;International Journal of Pharmaceutics: X;2024-06

5. Assessing and mitigating pH-mediated DDI risks in drug development – formulation approaches and clinical considerations;Drug Metabolism Reviews;2024-05-03